ONCORAL PHARMA ApS Financials, key figures and credit report
Gross profit -1 617.5 kDKK FY 2025 -341% vs 2024
EBIT -1 617.5 kDKK FY 2025 -341% vs 2024
Net debt 35 582.5 kDKK FY 2025 +6.9% vs 2024
Quick ratio 0.4 FY 2025 +0 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -13 819.76 | -7 461.59 | - 996.23 | - 366.79 | -1 617.54 |
| EBIT | -13 819.76 | -7 461.59 | - 996.23 | - 366.79 | -1 617.54 |
| Other financial income | 446.76 | 393.56 | 560.71 | 297.85 | 2 164.42 |
| Other financial expenses | -1 102.64 | -3 494.76 | -2 442.53 | -4 053.71 | -2 860.05 |
| Pre-tax profit | -14 475.65 | -10 562.79 | -2 878.04 | -4 122.65 | -2 313.17 |
| Income taxes | 2 657.55 | 1 355.90 | 210.80 | 64.81 | |
| Net earnings | -11 818.10 | -9 206.89 | -2 667.24 | -4 057.83 | -2 313.17 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Development expenditure | 87.50 | 87.50 | 87.50 | 87.50 | 87.50 |
| Intangible assets total | 87.50 | 87.50 | 87.50 | 87.50 | 87.50 |
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Prepayments and accrued income | 68.21 | 45.47 | 27.74 | ||
| Current other receivables | 989.82 | 342.25 | 17.86 | 26.96 | 37.66 |
| Current deferred tax assets | 2 658.37 | 1 355.90 | 210.80 | 64.81 | |
| Short term receivables total | 3 716.40 | 1 743.62 | 256.39 | 91.77 | 37.66 |
| Cash and bank deposits | 11 082.08 | 7 766.16 | 9 139.15 | 499.58 | 783.28 |
| Cash and cash equivalents | 11 082.08 | 7 766.16 | 9 139.15 | 499.58 | 783.28 |
| Balance sheet total (assets) | 14 885.97 | 9 597.28 | 9 483.05 | 678.85 | 908.44 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 145.92 | 145.92 | 145.92 | 145.92 | 145.92 |
| Retained earnings | -5 585.97 | -17 404.07 | -26 610.96 | -29 278.21 | -33 336.04 |
| Profit of the financial year | -11 818.10 | -9 206.89 | -2 667.24 | -4 057.83 | -2 313.17 |
| Shareholders equity total | -17 258.16 | -26 465.04 | -29 132.29 | -33 190.12 | -35 503.29 |
| Non-current owed to group member | 26 653.25 | 28 748.02 | 28 361.64 | 32 415.35 | 34 519.46 |
| Non-current liabilities total | 26 653.25 | 28 748.02 | 28 361.64 | 32 415.35 | 34 519.46 |
| Current trade creditors | 318.38 | 169.42 | 24.68 | 65.18 | 7.50 |
| Current owed to group member | 4 977.74 | 6 966.45 | 10 163.79 | 1 355.44 | 1 846.28 |
| Other non-interest bearing current liabilities | 194.76 | 178.44 | 65.23 | 33.00 | 38.50 |
| Current liabilities total | 5 490.88 | 7 314.31 | 10 253.69 | 1 453.62 | 1 892.27 |
| Balance sheet total (liabilities) | 14 885.97 | 9 597.28 | 9 483.05 | 678.85 | 908.44 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated